Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Adam Suleman, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, Michael Sebag, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Heidi Simmons, Monica Gallucci, George A. Tomlinson, Neil Berinstein

Blood (2024) 144 (Supplement 1): 6291.

https://doi.org/10.1182/blood-2024-203317

Published: 2024

Journal Articles

Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Michael P. Chu, Zack Breckenridge, Deanna Hockley, Mona Shafey, Sunil J. Desai, Victor A. Lewis, Peng Wang, Vladimir Sapon-Cousineau, Charles Yin, Carina Debes-Marun, Irwindeep Sandhu

Blood (2024) 144 (Supplement 1): 3464.

https://doi.org/10.1182/blood-2024-209646

Published: 2024

Journal Articles

Improving the Utilization and Tolerability of Thiotepa-Based Autologous Stem Cell Transplantation in Primary CNS Lymphoma

Robert Puckrin, Colin Stewart, Carolyn Owen, Lesley E. Street, Sarah Perry, Peter Duggan, Mona Shafey, Neil Chua, Douglas A. Stewart

Blood (2023) 142 (Supplement 1): 3595.

https://doi.org/10.1182/blood-2023-178085

Published: 2023

Journal Articles

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Neil Berinstein, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Monica Gallucci, Heidi Simmons

Blood (2023) 142 (Supplement 1): 3037.

https://doi.org/10.1182/blood-2023-186347

Published: 2023

Journal Articles

Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

Colin Stewart, Carolyn Owen, Neil Chua, Anthea Peters, Mona Shafey, Douglas A. Stewart, Robert Puckrin

Blood (2023) 142 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2023-178097

Published: 2023

Journal Articles

Real-World Outcomes of Consolidative Autotransplant for High-Risk Large B-Cell Lymphoma

Robert Puckrin, Russell Sterrett, Neil Chua, Carolyn Owen, Peter Duggan, Mona Shafey, Douglas A. Stewart

Blood (2022) 140 (Supplement 1): 10581–10582.

https://doi.org/10.1182/blood-2022-162850

Published: 2022

Journal Articles

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP

Douglas A. Stewart, Lois E. Shepherd, Jill J. Dudebout, Jean-François Larouche, Neil Chua, Tara Baetz, Michael Crump, Mona Shafey, Nizar Abdel-Samad, Sue Robinson, Isabelle Fleury, Deborah Marcellus, Pamela Skrabek, Jesse Kelly, Annette E. Hay, Bingshu Chen, John Kuruvilla

Blood (2022) 140 (Supplement 1): 3734–3736.

https://doi.org/10.1182/blood-2022-163706

Published: 2022

Journal Articles

Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Michael P. Chu, Zack M. Breckenridge, Andrew Daly, Mona Shafey, Victor A. Lewis, Sunil J. Desai, Peng Wang, Joseph Brandwein, Peter Duggan, Beverly Wilson, Bindu Thapa, Carina Debes-Marun, Irwindeep Sandhu

Blood (2022) 140 (Supplement 1): 7466–7467.

https://doi.org/10.1182/blood-2022-165887

Published: 2022

Journal Articles

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Neil L Berinstein, Gail Klein, Katerina Welsh, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed A Aljama, Jean-François Larouche

Blood (2022) 140 (Supplement 1): 9383–9384.

https://doi.org/10.1182/blood-2022-169245

Published: 2022

Journal Articles

Favorable Outcomes with Thiotepa/Busulfan-Based Conditioning and Autotransplant for Patients with Aggressive B-Cell Lymphoma and Secondary CNS Involvement

Robert Puckrin, Neil Chua, Mona Shafey, Douglas A. Stewart

Blood (2021) 138 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2021-146103

Published: 2021

Journal Articles

Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis

Marta Davidson, MDPhD, Douglas A. Stewart, Peter Duggan, MD FRCPC, Andrew Daly, MD, Mona Shafey, MD

Blood (2017) 130 (Supplement 1): 4534.

https://doi.org/10.1182/blood.V130.Suppl_1.4534.4534

Published: 2017

Journal Articles

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Wilson Lam, MD, Jan Storek, MD PhD, Nizar J Bahlis, MD, Christopher Brown, MD, Peter Duggan, MD FRCPC, Michelle Geddes, MD FRCPC, Mary Lynn Savoie, MD FRCPC, Mona Shafey, MD FRCPC, Douglas A. Stewart, MD FRCPC, Andrew Daly, MD FRCPC

Blood (2014) 124 (21): 3901.

https://doi.org/10.1182/blood.V124.21.3901.3901

Published: 2014

Journal Articles

Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

Lesley E. Street, MD, FRCPC, Nizar J. Bahlis, MD, Karen Valentine, MD, PhD, Deirdre A. Jenkins, MD, FRCPC, Carolyn J Owen, MD, FRCPC, Mona Shafey, MD, FRCPC, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCPC

Blood (2012) 120 (21): 2003.

https://doi.org/10.1182/blood.V120.21.2003.2003

Published: 2012

Journal Articles

Preference of Patients and Physicians Concerning Treatment Options for Relapsed Follicular Lymphoma: A Discrete Choice Experiment.

Mona Shafey, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Thuan Do, MD, FRCPC, Sasha Lupichuk, MD, FRCPC

Blood (2009) 114 (22): 4350.

https://doi.org/10.1182/blood.V114.22.4350.4350

Published: 2009

Journal Articles

Factor XIII Val34Leu Polymorphism and the Risk of Myocardial Infarction: A Meta-Analysis.

Mona Shafey, BSc, MD, Josdalyne L. Anderson, B.Sc, Dimitrios Scarvelis, MD, Steve P. Doucette, B.Sc, France Gagnon, PhD, Philip S. Wells, M.Sc., MD

Blood (2005) 106 (11): 1637.

https://doi.org/10.1182/blood.V106.11.1637.1637

Published: 2005

NARROW

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Improving the Utilization and Tolerability of Thiotepa-Based Autologous Stem Cell Transplantation in Primary CNS Lymphoma

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

Real-World Outcomes of Consolidative Autotransplant for High-Risk Large B-Cell Lymphoma

Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Favorable Outcomes with Thiotepa/Busulfan-Based Conditioning and Autotransplant for Patients with Aggressive B-Cell Lymphoma and Secondary CNS Involvement

Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

Preference of Patients and Physicians Concerning Treatment Options for Relapsed Follicular Lymphoma: A Discrete Choice Experiment.

Factor XIII Val34Leu Polymorphism and the Risk of Myocardial Infarction: A Meta-Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only